September 2019, Vol. 32(Suppl. 3): 01-36
© 2019 Sociedad Española de Quimioterapia
• Ceftobiprole review
Introduction
PEDRO LLINARES, JOSÉ BARBERÁN, JOSÉ MENSA
Rev Esp Quimioter 2019; 32 (Suppl. 3): 1-2.
Mechanisms of action and antimicrobial activity of ceftobiprole
MARÍA-ISABEL MOROSINI, MARÍA DÍEZ-AGUILAR, RAFAEL CANTÓN
Rev Esp Quimioter 2019; 32 (Suppl. 3): 3-10.
Ceftobiprole: pharmacokinetics and PK/PD profile
JOSÉ RAMÓN AZANZA PEREA, BELÉN SÁDABA DÍAZ DE RADA
Rev Esp Quimioter 2019; 32 (Suppl. 3): 11-16.
Ceftobiprole for the treatment of pneumonia
CATIA CILLÓNIZ, CRISTINA DOMINEDÒ, CAROLINA GARCIA-VIDAL, ANTONI TORRES
Rev Esp Quimioter 2019; 32 (Suppl. 3): 17-23.
Ceftobripole: Experience in staphylococcal bacteremia
ALEX SORIANO, LAURA MORATA
Rev Esp Quimioter 2019; 32 (Suppl. 3): 24-28.
Possible clinical indications of ceftobiprole
JOSÉ BARBERÁN
Rev Esp Quimioter 2019; 32 (Suppl. 3): 29-33.
Safety and tolerability of ceftobiprole
SANTIAGO GRAU
Rev Esp Quimioter 2019; 32 (Suppl. 3): 34-36.
